In this paper we review evidence concerning the impact of hematopoietic SCT (HSCT) on sexuality. The aims are to determine: (1) the sexual changes experienced by patients following allogeneic or autologous HSCT, and its consequences; (2) changes in the sexual function over time and (3) the impact of physiological changes induced by intensive treatment with radiation and chemotherapy on sexual functioning. Four databases were searched for articles published between January 1995 and May 2011. A total of 14 studies were identified and analyzed. We found that (1) multiple aspects of sexuality were affected, and the impact and etiology of these sexual alterations were different between genders, and (2) recovery of sexual activity and pleasure occurred in the first 2 years after HSCT, although it appears that some survivors are more likely to experience sexual dysfunction even 5-10 years after HSCT as compared with controls; and (3) there was contradictory evidence concerning possible differences between allogeneic and autologous HSCT, although there was a significant relation between the sexual dysfunctions and the type of chemotherapy administrated as conditioning and chronic GVHD. Future prospective research in sexual dysfunction with specific reliable validated instruments and more adequate sample sizes will be required to definitively evaluate the impact of HSCT on sexuality.
Introduction
As survival rates for hematopoietic SCT (HSCT) improve, there is subsequently an increased need for addressing longterm complications. [1] [2] [3] High-dose radiation and chemotherapy are associated with numerous short-and long-term toxicities, which can result in alterations in sexual functioning and satisfaction. [4] [5] Although the impact of a lifethreatening disease on sexuality may not be the first or most immediate concern for patients undergoing HSCT, this is an important and sometimes overlooked aspect of recovery and quality of life (QOL) following treatment. 4 Little is known about sexual changes and their consequences experienced by patients following allogeneic or autologous HSCT. This emphasizes an increased need for scientific evidence in this field of study.
Sexual dysfunction is a frequently described problem in QOL studies after HSCT. It is defined as one of the most common long-term issues following both allogeneic and autologous HSCT. [6] [7] [8] The long-term sexual complications include decreased libido, vaginal alterations, erectile and ejaculatory dysfunctions, premature menopause, dysfunction in sexual hormones, dyspareunia and infertility. 2, 4, 9, 10 One of the major determinants of sexual dysfunction in allogeneic HSCT patients is acute or chronic GVHD. 9, 8 GVHD can manifest anywhere in the body; however, in the genitals, it can lead to vaginal stenosis, scar tissue and adhesions in blood vessels, rash and increased sensitivity in the skin around the penis. 1, 11, 12 GVHD and treatment with high-dose corticosteroids may induce changes in physical appearance to such an extent that sexuality and body image are seriously affected. Body image changes, anxiety, depression, decreased self-confidence, fear of disease recurrence, concurrent life stress and concerns about infertility are some of the psychological factors that may disrupt the sexual response cycle. [13] [14] [15] Sexuality is a central part of one's identity, self-esteem and QOL. Furthermore, sexuality and intimacy can reduce emotional distress and improve psychosocial response to cancer diagnosis and complications following treatment. 16, 17 However, discussion of sexual functioning has long been a subject of taboo in the healthcare system. Thus, sexual functioning is one QOL variable, in particular, that needs further research, and it is necessary to draw attention to the impact that HSCT has on the sexuality and sexual functioning in patients after HSCT. In order to improve options for preventive or therapeutic interventions in this field, qualitative studies alone are not adequate. Research on the physiological aspects of sexual functioning after intensive chemo-and radiation therapy is also needed. Previous reviews have raised questions regarding the impact of HSCT on sexuality and addressed the issue of sexual dysfunction but not systematically, which is necessary because of the lack of scientific evidence in this field of study. 1, 4 This systematic review is, to our knowledge, the first to address this specific subject and patient group. We conducted a systematic literature search of the empirical evidence to determine (1) the sexual changes experienced by patients following allogeneic or autologous HSCT and its consequences; (2) changes in sexual function over time and (3) the impact of physiological changes induced by intensive treatment with radiation and chemotherapy on sexual functioning.
Methods
To ensure a systematic literature search, recommended review methods were used.
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Search strategy
The literature review covers 16 years of research, 1995-2011. Searches were performed in Medline, CINAHL, PsycINFO and the Science Citation Index (SCI)-EX-PANDED (Table 1) by using the keywords 'Sexuality', 'sexual dysfunction', 'Sexual Functioning', 'Hematopoietic Stem Cell Transplantation', 'Bone Marrow Transplantation', 'Stem Cell Transplantation', 'Graft versus Host Disease', 'Body Image', 'Allogeneic', 'Autologous', 'Genital disease', 'erectile dysfunction', 'vaginal' and 'ejaculation'. Identified articles were searched for additional references. The eligibility criteria are shown in Table 2 .
Data extraction
Articles that did not meet the eligibility criteria were identified from the abstracts and disregarded. Full articles were obtained for the remaining abstracts. Information was extracted from the identified articles and organized under the headings reference, type of treatment, instruments, procedure and major findings (Table 3 ). All articles were independently reviewed and discrepancies in coding were resolved through discussions among the authors. The studies were critically appraised for rigor of method and analysis.
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Results
Sixty-six studies were identified as potentially relevant and 14 met the inclusion criteria. [6] [7] [8] [9] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The majority of these, 4 each, came from the United States and the United Kingdom, 2 from Germany and 1 each from Canada, Ireland, The Netherlands and Finland.
Research design and purposes
The design in nine studies was retrospective cross-sectional, and the range from HSCT to questionnaire assessment was 4-228 months (mean 40.3). 6, [22] [23] [24] [25] [27] [28] [29] Five studies were prospective designs, with follow-up periods from 1 to 10 years. 6, 8, 9, 27, 30 Case-matched controls were used in four studies. 8, 27, 28, 30 Eight studies focused primarily on sexuality and sexual dysfunction, [6] [7] [8] [9] 22, 26, 27, 29 and five studies focused primarily on QOL/late effects, with a secondary focus on sexual function. [23] [24] [25] 28, 30, 31 The type of HSCT was allogeneic in five studies, autologous in two and both allogeneic and autologous in six studies.
Sample characteristics
The sample size in the studies ranged from 16 to 479 (mean 160.8). Respondents were all recruited from their treatment clinic at national hospitals. In case-matched control studies, the controls were primarily enlisted by the respondents, 8, 30 but in two studies it was not precisely described from where the control groups were recruited. 27, 28 The demographic characteristics of the respondents were included in all the papers. The respondents were mostly equally mixed genders, but in one study there was twice as many males as females, 28 and in two studies there were only male respondents. 28, 29 The age of the respondents ranged from 15 to 68 years (mean 40.2).
Study findings
Sexual functioning following treatment by HSCT. All 14 reviewed studies identified sexual dysfunction in patients following HSCT. Significantly worsened psychosexual functioning was found in HSCT patients as compared with healthy subjects (Po0.05), and nearly half of the patients (48.1%) were dissatisfied with their quality of sexual life following treatment. 27 Sexual functioning in HSCT patients decreased significantly and was poorer when compared with patients treated with chemotherapy alone (Po0.001). 6 Both men and women experienced a reduction in quality and quantity of sexual function from before HSCT to 6 months afterward. 8 Following HSCT 45% males and 33% females experienced a decline in their sexual life quality. 28 The studies found a variety of problems with desire and function problems, which in some studies were present at 
Questionnaire: EORTC-QLQc30, DSM-IV, leukemia-BMT-specific module and a short section on sexual functioning, fertility and late effects A retrospective cross-sectional study. The evaluation period ranged from 34 to 217 months after treatment. Questionnaires were sent to all survivors by letter Patients experienced a decrease in sexual activity (38%), in the ability to have sex (36%), pleasure from sex (31%) and interest in sex (28%).
Patients atyounger age (o35 years) had the same or an increased level of sexual activity after HSCT compared with patients at older age (435) (P ¼ 0.023). Chronic GVHD was diagnosed in 48% of the survivors, but no comparisons in sexuality were made
Gruber et al. For males, a longer follow-up time and less severe chronic GVHD were related to higher satisfaction with sexual life. Chronic GVHD was significantly associated with lower emotional well-being among the female recipients and with less sexual satisfaction among the male subjects PAIS, blood samples (FSH, LH and total testosterone levels)
A retrospective cross-sectional study. The evaluation period ranged from 7 to 96 months after treatment.
The assessment was conducted in the ambulatory clinic All patients had abnormal hormone levels with elevated FSH (88%), LH (48%) and decreased serum testosterone levels (38%). A significant correlation was found between decreased testosterone levels and moderate-to-total loss of interest in sexual activities (P ¼ 0.008). A moderate-to-total loss of interest in sexual activities was found in 25%
Watson et al. Aspects of sexual functioning showed a decrease in sexual activity (38%) and in the ability to have sex (36%), pleasure from sex (31%) and interest in sex (28%). 24 One study found that both male and female survivors frequently reported specific sexual problems such as vaginal dryness, dyspareunia or erectile dysfunction (P ¼ 0.01 for males and P ¼ 0.001 for females). 30 This was supported by Claessens et al. 22 who found that men experienced a delay or absence of orgasm/ejaculation (38%) and erectile dysfunction (74%) more often than before HSCT. Furthermore, 25% males experienced erectile dysfunction always or often. 22 Both men and women had sexual function prior to HSCT that was below that in the control persons. Furthermore, there was a significant difference in sexual activity between male 5-year survivors and matched controls (P ¼ 0.04). At least 40% of the female survivors were not sexually active at any time point (1, 2, 3 and 5 years after HSCT) as compared with 21% female controls. 8 There was a significant correlation at 3 years after HSCT between patients who had a discussion with their healthcare provider about the treatment's effect on sexuality and those who reported fewer sexual functioning problems (P ¼ 0.02). Gender-associated differences in sexuality. There was significant gender-by-time interaction (P ¼ 0.017), whereby women's problems increased dramatically over time (1 and 3 years after HSCT), whereas men's problems remained more stable. 9 Females when compared with males reported more problems with interest in sex (Po0.001), sexual activity (P ¼ 0.02) and pleasure from sex (Po0.001). 6 In addition, women reported a greater number of problems than men across all three time periods (baseline, 1 and 3 years after HSCT) (Po0.001). 9 Eighty percent of women reported one or more sexual problems at 3 years after HSCT, in contrast to 29% of men (Po0.001). Furthermore, women consistently reported significantly less interest than men (baseline, 1 and 3 years after HSCT) (Po0.001). 9 Conversely, one study reported no gender difference in sexual satisfaction. 31 Humphreys et al. 7 found a significant relationship between gender and total sexual problems, with females reporting more problems than men (P ¼ 0.04), and women reporting more sexual problems at 1 year across all categories. Men had more concerns with their physical appearance and problems with obtaining an erection, ejaculation and orgasm 1 year after HSCT. Women experienced problems with lack of sexual interest, appearance, vaginal dryness and painful intercourse 1 year after HSCT. 7 In addition, men had higher rates of sexual activity compared with women across time (baseline, 6 months, 1, 2, 3 and 5 years after HSCT). 8 Furthermore, a significant difference between male survivors and male controls 5 years after HSCT was found in relation to reported sexual problems (P ¼ 0.05). This correlation was also found in female survivors and controls 5 years after HSCT (P ¼ 0.01). 8 In addition, a longer follow-up time and less severe chronic GVHD were related to higher satisfaction with sexual life in male survivors. 9 This was supported by Syrjala et al. 8 who found that by 2 years after HSCT men's scores improved, as compared with 6 months after HSCT (P ¼ 0.02).
Treatment-related sexual problems. A difference was found between allogeneic and autologous HSCT on the ability to have sex (P ¼ 0.07), with more allogeneic patients reporting changes in the ability to have sex. 6 Conversely, two other studies reported no difference between these two treatment groups and sexual function. 26, 28 However, one study found a significant difference (P ¼ 0.02) between allogeneic HSCT patients and maintenance chemotherapy patients in relation to impotence-related difficulties, with maintenance chemotherapy patients having less difficulties. 28 In addition, Molassiotis et al. 27 also found that overall psychosexual functioning, impotence-related difficulties (Po0.001) and altered body image (Po0.001) were associated with the type of chemotherapy administered during the conditioning regimen. Patients who had received BU combined with a CY or UCH protocol (CY, doxorubicin, carmustine and 6-thioguanine) as conditioning had greater impotence, body image and psychosexual difficulties compared with patients who had received only CY or BEAM. 27 There is contradicting evidence on the association between sexual dysfunction and GVHD in allogeneic HSCT patients. Watson et al. 6 found no significant evidence relating chronic GVHD and an adverse impact on sexual functioning. However, the percentage of patients who experienced sexual dysfunction was higher in those with GVHD, suggesting that GVHD increases sexual dissatisfaction. 6 Conversely, one study found that chronic GVHD was significantly associated with lower emotional well-being among female recipients and with less sexual satisfaction among male subjects. 24 This was supported by Syrjala et al. 9 who found that women who reported arousal problems had more extensive chronic GVHD in the first year (Po0.05) and women with orgasm problems had more severe residual chronic GVHD at the third year (Po0.05). There was no correlation between GVHD in the genitals and sexual dysfunction. 9 Hormonal disorders were more common in allogeneic than in autologous patients (P ¼ 0.02). 6 Patients treated for hormone deficiencies were also more likely to have poorer sexual functioning in each case (Po0.001). 6 Three studies found abnormal hormone levels in their patient groups. 22, 27, 29 In addition, Schimmer et al. 29 found that all patients had abnormal hormone levels with elevated follicle-stimulating hormone (88%), elevated luteinizing hormone (LH) (48%) and decreased serum testosterone levels (38%), with a significant correlation between decreased testosterone levels and moderate or total loss of interest in sexual activities (P ¼ 0.008).
Emotional well-being. There was a significant correlation between sexual functioning and increased fatigue, decreased emotional functioning and global QOL (Po0.001 in each case). 6 Allogeneic HSCT patients reported significantly poorer QOL as compared with autologous and consolidation chemotherapy patients. 6 In addition, a significant correlation was found between decreased sexual activity and poorer emotional functioning (Po0.001). 6 Furthermore, QOL was significantly correlated with sexual relationship (Po0.05). 28 This was supported by Gruber et al. 31 who found a positive correlation between anxiety/ emotional stress, pain, stress in partnership/family and sexual problems. Survivors (32%) were dissatisfied with their sexual appeal and reported that they were dissatisfied with their appearance (17%) as compared with before the allogeneic HSCT. 25 This agrees with the results of Humphreys et al. 28 who found that men experienced more concern with their body appearance 3 years after HSCT than at other points of time (baseline and 1 year after HSCT). In addition, depression was significantly and positively related to desire (P ¼ 0.02), physical function (P ¼ 0.02) and overall problems at baseline and at 3 years after HSCT. Sexual problems persist in some patients for many years. Although some recovery of sexual activity and pleasure occurs in the first 2 years after transplantation, survivors remain more likely than controls to experience sexual dysfunction even 5-10 years after their cancer treatment. 8, 30 A finding that highlights the importance of assessing sexual functioning early after treatment is that, for women in particular, if sexual activity has not returned within 1 year, these problems can persist for 5 years and possibly indefinitely. 9 Females reported a significantly greater number of problems than men across all time points, and were less likely than men to recover from sexual dysfunction. This is consistent with studies of sexual function in the general population and among cancer survivors, where men reported better sexual function compared to women. 32, 33 As differences, both in problem rates and satisfaction, are marked between males and females, it is necessary to consider the effects on these survivors separately.
Female HSCT survivors reported significantly higher rates of sexual dysfunction as compared with controls. 8 The reported sexual dysfunction included lack of sexual interest, alterations in body image, vaginal dryness, vaginal tightness, fibrosis and painful intercourse. 7 These alterations most likely result from a combination of conditioning regimen, premature menopause and vaginal chronic GVHD. In females, the conditioning regimen in HSCT causes a decreased secretion of sexual hormones, including oestrogen, inducing symptoms of menopause with hot flushes, depression, vaginal dryness, vaginal atrophy and fibrosis, urogenital symptoms and changes in appearance and cognitive function. 1, 4 Male survivors also reported significantly higher rates of sexual dysfunction compared with controls. 8 Males had concerns about their physical appearance and problems obtaining an erection, ejaculation and orgasm. 7, 24 Radiation and chronic GVHD can cause sexual dysfunction in males by a more direct action, causing inflammation, rash and sensitivity in the skin of the penis. 10 The results indicated a significant difference between allogeneic and autologous patients in relation to hormonal disorders and poorer sexual functioning, 6, 8, 29 indicating an impact of either more intensive conditioning or GVHD, or both. In males, damage to the gonads from the conditioning regimen causes a loss or reduction in the secretion of sexual hormones and elevations in the levels of follicle-stimulating hormone, which is the hallmark of gonadal failure. A significant correlation between hormonal dysfunction and moderate-to-total loss of interest in sexual activities was found. 29 Changes in hormone levels and neurovascular damage may disrupt the desire, arousal or orgasmic phase of the sexual response cycle and adversely affect sexual functioning and satisfaction in men following HSCT.
Many of these problems are similar to the ones experienced by other cancer patients. The extent of symptoms is not surprisingly correlated to the intensity of treatment with chemotherapy, total-body irradiation and medications for side effects. 1, 32 High-dose chemotherapy, especially alkylating agents and total-body irradiation, are toxic to gonadal function and can contribute to genital tissue sensitivity, atrophy or scarring. 34 Psychosexual functioning, impotence-related difficulties and altered body image were significantly correlated with the type of chemotherapy administered. 27 This may explain why significant differences occurred between patients undergoing allogeneic HSCT and patients receiving maintenance chemotherapy with respect to impotence-related difficulties. 27 Efforts to reduce the toxicities of HSCT have utilized reduced-intensity chemotherapies and total-body irradiation followed by HSCT. This may spare gonadal function along with other organ systems, but risks for chronic GVHD remain. In addition, chronic GVHD most likely contributes to some of these sexual dysfunctions in patients undergoing allogeneic HSCT.
Two studies significantly associated chronic GVHD in allogeneic HSCT patients with lower emotional well-being, less sexual satisfaction, arousal and orgasm problems. 9, 24 One study found no significant evidence in this context, although the percentage of patients with these problems was higher in the group with GVHD. 6 These contradicting results may be due to inadequate sample size and whether GVHD was active or historical when questionnaire assessment was made. Chronic GVHD can manifest anywhere in the body; however, in the genitals in particular, it is a major possible determinant for sexual dysfunction. In female patients, it can contribute to vaginal stenosis, mucosal changes, vaginal irritation, bleeding and increased sensitivity of genital tissues. 11, 12, 35 The incidence rate for genital GVHD in females is reported in one study to be approximately 35%. 11 In males it contributes to scarring or adhesions in the blood vessels of the penis, skin sensitivity, and gonadal and cavernosal arterial insufficiency, with resulting libido and erectile dysfunction. 1, 10 Genital GVHD is directly related to chronic GVHD in other organs, for example mouth, skin and the gastrointestinal tract. 11 Furthermore, as GVHD diminishes in other parts of the body and medication is tapered, GVHD in the genital area remains or develops after resolving in other organs. 1 Chronic GVHD is managed by the use of immunosuppressants that often include high-dose corticosteroids. This treatment is well-known for having a major impact on physical features and body image along with potential for emotional lability and depression.
1 These changes combined with physiological alterations may severely affect the feelings of attractiveness, sexual selfconsciousness, sexual activity and quality of sexual life.
Body image changes were identified in some patients following their HSCT treatment. 7, 25 Appearance changes include hair loss, muscle loss, skin rashes, skin sensitivity or dryness, scars, weight changes and edema especially of the face. 1, 4, 36 Altered body image may disrupt feelings about the self as a sexual being. In a study of HSCT recipients, high levels of global psychological distress were correlated with less sexual satisfaction, poorer body image and increased disruption in sexual relationship. 37 Poorer sexual function correlated significantly with decreased emotional functioning and global QOL. 6, 28, 32 This indicates that sexual function is an important aspect of QOL, and it is important to recognize whether a patient is experiencing sexual problems. In this context, it is necessary to emphasize that QOL was significantly poorer in allogeneic HSCT patients as compared with autologous patients. 6 Chiodi et al. 38 found in a QOL study that onethird of patients undergoing allogeneic HSCT reported a poor QOL. This can be due to chronic GVHD being the most frequent cause of poor long-term outcome and QOL after allogeneic HSCT. 39 This finding is consistent with the study of Lee et al. 40 who found that GVHD is a major determinant of the long-term QOL in survivors of allogeneic HSCT and chronic GVHD to be most strongly correlated with impaired QOL. Although there is contradicting evidence in connection with the association between type of HSCT and sexual dysfunction, 6, 26, 28 it underlines the importance of sexuality as a QOL variable in future studies, especially in allogeneic HSCT patients.
In general, patients indicated that their healthcare provider did not discuss the potential effects of HSCT on their sexual health. 7, 22 In addition, discussion with a healthcare provider reduced their sexual problems significantly. 7 It is therefore necessary to discuss sexuality on par with discussions of the disease, its treatment, and other symptoms or problems. This also indicates to the patient that sexuality is a legitimate topic and can be discussed again at a later time, if desired. Discussing sexual issues emphasizes the importance of maintaining normal activity and relationships during treatment and recovery.
Methodological discussion
Our conclusions are limited by the modest number of research studies addressing the issue of the impact of HSCT on sexuality. In addition, the studies included were found to be diverse in purpose, study design, sample size and study population. A number of methodological problems limit the applicability of the available research and need to be addressed.
The diversity of these studies was particularly expressed in different ranges of test periods (4-228 months) from HSCT to questionnaire assessment. The long-term complications, including sexual dysfunction, correlate with the time after HSCT and are different in terms of causes, reversibility and prevalence, factors that highly affect the results' generalization and validity. This affects the reliability of this research because it is impossible to prove the correlation between sexual dysfunction and treatment with HSCT. Small sample sizes are limitations of past research, with some studies using as few as 16 participants, making it difficult to compare the reviewed studies and we must question the validity and reliability of the statistical analysis in those studies. In addition, many studies have used mixed patient samples, which include individuals who have received autologous and allogeneic HSCT, despite findings indicating significant differences. Attrition rates of up to 67.9% were described, 7, 22, 25 which may be a result of the severity of the long-term complications following HSCT, patients experiencing sexual problems and refusal to participate, the recruitment of participants and the fact that sexuality is still a taboo to many. At least some studies reported the reason why people refused to participate. 22, 26 The strengths of the reviewed studies are that, they mostly use validated standard assessment measures, which increases the results' validity and reliability. The various questionnaires measure sexuality differently, which in some cases makes it complicated to perform comparisons. In addition, some studies were case-control studies, which may strengthen the evidence of the correlation between HSCT and impact on sexuality. A possible limitation in some studies was that the matched controls, if described, were not randomly designated. Using siblings and friends as controls with similar biology, lifetime exposure and social environment is standard for survivorship research. However, this method could be susceptible to bias.
Research implications
Evidence strongly suggests that sexual dysfunction is one of the most prevalent and persistent long-term problems after HSCT, but there are still gaps in the research that need to be filled. Much of the research has been conducted with patients who were in committed relationships and/or sexually active, but little is known about the sexual functioning, needs or concerns of people who are single and/or sexually inactive. We do not know the difference as to the impact on sexuality between myeloablative and nonmyeloablative allogeneic HSCT patients, although there is a great difference in the conditioning regimens prior to HSCT. There is no research that has specifically investigated the correlation between sexual dysfunction and GVHD, even though chronic GVHD has a high potential influence on the patient's sexuality. In this context, it is important that the researcher, and not the patient, register GVHD by measuring the graduation of type and severity of GVHD. In addition, it is relevant to make a corresponding correlation with body image because of the possible connection between GVHD, altered body image and sexual dysfunction. It is necessary to perform a baseline assessment before treatment with HSCT in order to recognize the impact of HSCT on sexual function. There is a need for consensus in the selection of questionnaires evaluating sexuality in order to perform reliable and valid comparisons between studies. Future prospective research in sexual dysfunction with specific reliable validated instruments and more adequate sample sizes are necessary to definitively evaluate the impact of HSCT on sexuality.
Future treatment-related studies are needed because of the physical and psychological influence of HSCT on sexuality. Medical treatment exists for treatment of sexual dysfunction. However, there is lack of evidence on the efficacy of hormones for sexual dysfunction and the riskbenefits of hormone therapy. Evidence from other cancer populations suggest that a combination of approaches is likely to be most effective, using education, hormone evaluation, hormone therapy where indicated, topical or behavioral strategies and couples' intervention. 41, 42 No study has yet tested this combination of therapies to address sexual dysfunction after HSCT. The need for studies of treatment in this area cannot be overstated given the prevalence of the problems.
Conclusion
This review of the literature confirms that patients receiving treatment with HSCT experience several long-term sexual problems, including decreased libido and sexual activity, genital alterations, erectile and ejaculatory dysfunctions, and altered sexual appearance. There was a significant difference between the genders, with females reporting a greater number of problems than men across all points of time, and women being less likely to recover from sexual dysfunction. Few interventions have addressed the issues of treatment-related, physiologically induced sexual problems, including GVHD, despite chronic GVHD being strongly correlated with poorer QOL. The correlation between sexual dysfunction and chronic genital GVHD, as well as other physiological changes relating to sexual functioning, need to be addressed. Future research is required in order to evaluate alterations of sexuality, seen in HSCT patients, especially in allogeneic HSCT patients, in relation to GVHD. The diagnosis and treatment of a life-threatening illness can be extremely disruptive to a person's/patient's sexuality. Survivors of HSCT should be assessed for their sexual functioning prior to treatment so that any changes can be tracked over time and the appropriate treatment recommendations can be initiated. Hopefully this will lead to preventive interventions that may improve the QOL in HSCT patients.
